Actively Recruiting
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2025-11-20
150
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
Sponsors
S
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
P
Personal Genome Diagnostics
Collaborating Sponsor
AI-Summary
What this Trial Is About
Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Second, the investigators will investigate whether enacting upon MTB recommendations would improve outcomes in terms of progression-free and overall survival. Third, the investigators aim to determine if molecular profiling via serial plasma tests after initiation of chemotherapy or other targeted treatment is sufficient to determine whether or not a patient is responding to therapy.
CONDITIONS
Official Title
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status of 0-1
- Diagnosis of solid tumors including esophageal cancer, non-adenocarcinoma NSCLC, small-cell lung cancer, head and neck cancer, mesothelioma, breast cancer, or lung neuroendocrine cancer
- Ability to provide whole blood samples totaling 20-30ml at baseline, 1-3 weeks after treatment starts, at first imaging, and at progression
- Archival or time-matched tumor tissue sample preferred but not required, with at least 20% tumor content and 100 ng
- For metastatic disease, progression on most recent treatment prior to enrollment or imminent progression expected by oncologist
- Patients eligible for first-line standard treatments if efficacy is uncertain
- Disease evaluable for progression; measurable disease not required
- Able to give informed consent voluntarily
You will not qualify if you...
- Known pregnancy
- History of another primary cancer within the last 5 years unless approved by the Protocol Chair
- Prior in situ cancer or basal or localized squamous cell skin cancer are allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
Research Team
V
Valsamo Anagnostou, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here